Kinnari Patel

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial

John P. Neoptolemos, Daniel H. Palmer, Paula Ghaneh et al. · The Lancet · 2017 · 1.9K citations · Full text

Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · The Lancet Oncology · 2021 · 711 citations · Full text

Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma

Robert Jones, Eftychia‐Eirini Psarelli, Richard Jackson et al. · JAMA Surgery · 2019 · 256 citations · Full text

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Ángela Lamarca, Daniel H. Palmer, Harpreet Wasan et al. · Journal of Clinical Oncology · 2019 · 226 citations

Cancer Management, Prognosis, Pathology +17

Genomic and outcome analyses of Ph-like ALL in NCI standard-risk patients: a report from the Children’s Oncology Group

Kathryn G. Roberts, Shalini C. Reshmi, Richard C. Harvey et al. · Blood · 2018 · 127 citations · Full text